193 related articles for article (PubMed ID: 23244604)
1. Identification of functional DNA variants in the constitutive promoter region of MDM2.
Lalonde ME; Ouimet M; Larivière M; Kritikou EA; Sinnett D
Hum Genomics; 2012 Sep; 6(1):15. PubMed ID: 23244604
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene.
Liang H; Lunec J
Gene; 2005 Nov; 361():112-8. PubMed ID: 16202543
[TBL] [Abstract][Full Text] [Related]
3. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
4. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.
Lind H; Zienolddiny S; Ekstrøm PO; Skaug V; Haugen A
Int J Cancer; 2006 Aug; 119(3):718-21. PubMed ID: 16496380
[TBL] [Abstract][Full Text] [Related]
5. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells.
Hu W; Feng Z; Ma L; Wagner J; Rice JJ; Stolovitzky G; Levine AJ
Cancer Res; 2007 Mar; 67(6):2757-65. PubMed ID: 17363597
[TBL] [Abstract][Full Text] [Related]
6. p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours.
Dimitriadi M; Poulogiannis G; Liu L; Bäcklund LM; Pearson DM; Ichimura K; Collins VP
Br J Cancer; 2008 Oct; 99(7):1144-52. PubMed ID: 18781178
[TBL] [Abstract][Full Text] [Related]
7. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
8. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
9. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
10. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
11. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
12. MDM2 and its functional polymorphism SNP309 contribute to the development of esophageal carcinoma.
Xiao FK; Guo S; Yang F; Zhao LS; Wang LD
J Gene Med; 2019 May; 21(5):e3086. PubMed ID: 30861607
[TBL] [Abstract][Full Text] [Related]
13. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
14. Haplotype structure and selection of the MDM2 oncogene in humans.
Atwal GS; Bond GL; Metsuyanim S; Papa M; Friedman E; Distelman-Menachem T; Ben Asher E; Lancet D; Ross DA; Sninsky J; White TJ; Levine AJ; Yarden R
Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4524-9. PubMed ID: 17360557
[TBL] [Abstract][Full Text] [Related]
15. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.
Yu H; Huang YJ; Liu Z; Wang LE; Li G; Sturgis EM; Johnson DG; Wei Q
Mol Carcinog; 2011 Sep; 50(9):697-706. PubMed ID: 21656578
[TBL] [Abstract][Full Text] [Related]
16. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma.
Singhal P; Hussain S; Thakur N; Batra S; Salhan S; Bhambani S; Bharadwaj M
DNA Cell Biol; 2013 Jan; 32(1):19-27. PubMed ID: 23210739
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis.
Gansmo LB; Lie BA; Mæhlen MT; Vatten L; Romundstad P; Hveem K; Lønning PE; Knappskog S
Gene; 2021 Aug; 793():145747. PubMed ID: 34077778
[TBL] [Abstract][Full Text] [Related]
18. p53 Signaling Pathway Polymorphisms Associated With Emphysematous Changes in Patients With COPD.
Mizuno S; Ishizaki T; Kadowaki M; Akai M; Shiozaki K; Iguchi M; Oikawa T; Nakagawa K; Osanai K; Toga H; Gomez-Arroyo J; Kraskauskas D; Cool CD; Bogaard HJ; Voelkel NF
Chest; 2017 Jul; 152(1):58-69. PubMed ID: 28315337
[TBL] [Abstract][Full Text] [Related]
19. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
Zhang X; Pageon L; Post SM
Oncogene; 2015 Aug; 34(33):4412-20. PubMed ID: 25435368
[TBL] [Abstract][Full Text] [Related]
20. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
